Compare AbCellera Biologics Inc (ABCL) vs Franklin Resources, Inc. (BEN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Franklin Resources, Inc. — how do they compare? AbCellera Biologics Inc trades at $7.15 (market cap $2.35B), while Franklin Resources, Inc. trades at $33.41 (market cap $17.85B). The key difference: Franklin Resources, Inc. is far larger — about 7.6× AbCellera Biologics Inc's market cap, and Franklin Resources, Inc. pays a 3.84% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | BEN | |
|---|---|---|
Market Cap | $2.35B | $17.85B |
Sector | Health | Financials |
52-Week High | $8.12 | $34.44 |
52-Week Low | $2.78 | $21.18 |
Enterprise Value | $1.99B | $29.68B |
Dividend Yield | — | 3.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Franklin Resources (BEN) trades at $34.36, up 0.73% on the day, with a bullish technical signal from moving averages. The company reported three consecutive quarterly earnings beats, with Q2 2026 results expected on July 31, 2026. Revenue grew to $8.77 billion in 2025, and AUM increased to $1.79 trillion in June 2026, driven by net inflows and strategic expansions into alternatives and digital assets.
Outlook remains positive with earnings momentum and dividend yield near 4%, but risks include volatile cash flows and high P/E ratio. Analyst consensus is mixed with a $33 price target slightly below current levels, suggesting cautious optimism amid solid fundamentals and growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Franklin Resources, Inc.
Franklin Resources provides investment services for individual and institutional investors. At the end of August 2022, Franklin had $1.388 trillion in managed assets, composed primarily of equity (32%), fixed-income (38%), multi-asset/balanced (10%) funds, alternatives (16%), and money market funds (4%). Distribution tends to be weighted more toward retail investors (49% of AUM) investors, as opposed to institutional (49%) and high-net-worth (2%) clients. Franklin is also one of the more global firms of the U.S.-based asset managers with more than 35% of its AUM invested in global/international strategies and 25% of managed assets sourced from clients domiciled outside the United States.
Read more on BEN →
